Drug-Resistant Epilepsy

By Dovy Paukstys, Founder, Komori Care

This article is educational and is not medical advice. It does not diagnose, treat, prevent, or cure any condition. Komori is not a medical device, is not FDA-cleared, does not detect seizures, and is not intended for people with epilepsy. Talk with a neurologist or epileptologist about personal medical decisions. Households living with epilepsy should use clinically validated seizure-detection devices as directed by their care team.

"Refractory" gets thrown around after one bad month. ILAE was pickier than that.

I don't have epilepsy. I opened the ILAE Task Force paper (Kwan and colleagues, 2010) and the NINDS and CDC pages that sit next to it. The definition is a door into a better evaluation. It is not a personality label.

The sentence they landed on

Drug-resistant epilepsy: failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom.

That's the ILAE consensus proposal. They called it a testable hypothesis, not a stone tablet. They wanted a common language so clinics and studies would stop using 15 different definitions.

Two. Not five. They picked two on purpose so people wouldn't wait forever for a real evaluation. They also said it can be revised when better data shows up.

Adequate and appropriate actually mean something

A drug that was wrong for the seizure type does not count. ILAE's example: ethosuximide is usually not an appropriate trial for focal seizures.

A drug you stopped during the first week because of a rash, before it ever reached a useful range, is often "undetermined," not a failure of efficacy. Failed because it wasn't tolerated in titration is not the same as failed because seizures continued on an adequate trial.

They want a minimum dataset. What the drug was. How it was given. How long. Seizures and side effects during that stretch. Whether anyone tried to optimize the dose. Why it stopped.

If that information is missing, the trial is uninformative. Some people "fail" a pile of drugs before they fail two that were actually appropriate and informative. ILAE wrote that down so nonspecialists would stop over-counting.

Sustained seizure freedom, in their scheme, is freedom from all seizures, including auras, for at least 12 months, or three times the longest pre-treatment gap between seizures, whichever is longer. Treatment failure is recurrent seizures after the intervention was adequately applied.

I'm not turning that into a home worksheet. The point is: "I still had a seizure this month" is not automatically the ILAE definition by itself. Duration and adequacy matter.

It's a snapshot, not a life sentence

ILAE: drug responsiveness is a dynamic process, not a fixed state. Epilepsy can fluctuate. Classifying someone as drug resistant is valid at the time of assessment. It does not mean they will never become seizure-free later.

They also defined drug-responsive: seizure-free on the current regimen for that 12-month / rule-of-three window. And they left a lane called undefined, for people who haven't been on two informative trials yet, or haven't been followed long enough.

If someone meets the definition, the paper says that should prompt a comprehensive review of diagnosis and management, preferably at an epilepsy center. That's the useful part. Don't sit on the fifth random add-on for three more years because a forum said "just try one more."

What NINDS and CDC do with the same idea

NINDS: surgery is typically considered after a person has unsuccessfully tried at least two medications, or when a lesion is the likely cause. Same two-drug door.

CDC: medicines work for about 2 in 3. If seizures continue, tell the provider. See a neurologist or epileptologist if seizures don't stop. See a specialist if medicine isn't controlling them or side effects are ugly. An epilepsy center is for hard-to-control seizures.

NINDS's research overview puts the leftover group at about 25 to 30 percent who continue to have seizures even with the best available treatment, and calls that treatment-resistant epilepsy. Different wording, same neighborhood as ILAE.

What happens after the label

Review the diagnosis. Events that look like seizures are not always epileptic. NINDS spends a lot of space on nonepileptic events. Wrong diagnosis is a classic reason "two drugs failed."

Then the other categories. Surgery evaluation. Implanted stimulation. Medical ketogenic therapy. Those are other posts. The ILAE paper itself says the definition should push people toward specialist review so those options aren't delayed.

None of that is a consumer product path. A gadget does not make epilepsy drug resistant and does not unmake it. Komori is not a treatment, not a detector, not for people with epilepsy.

FAQ

What is the ILAE definition?

Failure of adequate trials of two tolerated, appropriately chosen and used antiseizure-drug schedules (alone or together) to achieve sustained seizure freedom. Kwan et al., ILAE Task Force, 2010.

Does stopping a drug after a week count?

Often no. ILAE treats trials that never became adequate (wrong drug, stopped in titration, missing data) as uninformative or undetermined, not automatic proof of drug resistance.

Does drug-resistant mean nothing will ever work?

No. ILAE says the classification is a snapshot. Some people later become seizure-free. The point of using two trials, not ten, is to get a proper evaluation sooner.

Who should I see if this sounds like us?

CDC: a neurologist or epileptologist, and an epilepsy center when seizures are hard to control. ILAE: fulfillment of the definition should prompt a comprehensive review, preferably at an epilepsy center.

Sources

• ILAE, Definition of drug resistant epilepsy (Kwan et al., 2010 PDF): https://www.ilae.org/files/ilaeGuideline/Definition-of-Drug-Resistant-Epilepsy-2009-1528-1167.2009.02397.pdf
• NINDS, Epilepsy and Seizures: https://www.ninds.nih.gov/health-information/disorders/epilepsy-and-seizures
• NINDS, Curing the Epilepsies: https://www.ninds.nih.gov/current-research/focus-disorders/epilepsy-research/curing-epilepsies-promise-research
• CDC, Treatment of Epilepsy: https://www.cdc.gov/epilepsy/treatment/index.html